Dongsheng Tu

38.8k total citations · 12 hit papers
313 papers, 25.5k citations indexed

About

Dongsheng Tu is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dongsheng Tu has authored 313 papers receiving a total of 25.5k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Oncology, 82 papers in Cancer Research and 79 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dongsheng Tu's work include Colorectal Cancer Treatments and Studies (61 papers), Breast Cancer Treatment Studies (40 papers) and Estrogen and related hormone effects (37 papers). Dongsheng Tu is often cited by papers focused on Colorectal Cancer Treatments and Studies (61 papers), Breast Cancer Treatment Studies (40 papers) and Estrogen and related hormone effects (37 papers). Dongsheng Tu collaborates with scholars based in Canada, United States and Australia. Dongsheng Tu's co-authors include Jun Shao, Lois E. Shepherd, Malcolm J. Moore, Derek J. Jonker, Lesley Seymour, Chris J. O’Callaghan, Christos S. Karapetis, Andrea Bezjak, John Zalcberg and Niall C. Tebbutt and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Dongsheng Tu

293 papers receiving 24.7k citations

Hit Papers

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer 1995 2026 2005 2015 2005 2008 2003 2007 1995 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
    2005 4.3k citations Dongsheng Tu, Lesley Seymour et al. New England Journal of Medicine profile →
  2. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
    2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. New England Journal of Medicine profile →
  3. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
    2003 1.6k citations Malcolm J. Moore, Stanley R. Hamilton et al. New England Journal of Medicine profile →
  4. Cetuximab for the Treatment of Colorectal Cancer
    2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. New England Journal of Medicine profile →
  5. The Jackknife and Bootstrap
    1995 1.4k citations Dongsheng Tu et al. profile →
  6. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
    2005 818 citations Dongsheng Tu, Lois E. Shepherd et al. JNCI Journal of the National Cancer Institute profile →
  7. Morphine, Gabapentin, or Their Combination for Neuropathic Pain
    2005 747 citations Ian Gilron, Dongsheng Tu et al. New England Journal of Medicine profile →
  8. Exemestane for Breast-Cancer Prevention in Postmenopausal Women
    2011 646 citations Patricia Farmer, Karen A. Gelmon et al. New England Journal of Medicine profile →
  9. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    2010 573 citations Derek J. Jonker, Dongsheng Tu et al. profile →
  10. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations Kathleen I. Pritchard, Karen A. Gelmon et al. New England Journal of Medicine profile →
  11. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
    2021 131 citations Tingyan Shi, Dongsheng Tu et al. profile →
  12. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
    2024 98 citations Dongsheng Tu, Lois E. Shepherd et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dongsheng Tu Canada 64 15.6k 8.6k 5.9k 4.3k 4.1k 313 25.5k
Eric J. Feuer United States 68 17.9k 1.1× 11.0k 1.3× 4.9k 0.8× 5.5k 1.3× 3.3k 0.8× 252 40.4k
Marc Buyse Belgium 80 15.5k 1.0× 7.7k 0.9× 6.3k 1.1× 5.4k 1.2× 2.8k 0.7× 404 29.0k
Elizabeth A. Eisenhauer Canada 61 15.2k 1.0× 12.7k 1.5× 7.3k 1.2× 12.0k 2.8× 2.8k 0.7× 213 41.9k
Kenneth R. Hess United States 98 15.4k 1.0× 14.8k 1.7× 8.5k 1.4× 9.9k 2.3× 3.5k 0.9× 509 41.8k
David S. Hong United States 77 10.4k 0.7× 6.3k 0.7× 5.8k 1.0× 9.5k 2.2× 2.7k 0.7× 817 23.2k
Denis Lacombe Belgium 34 15.2k 1.0× 14.2k 1.6× 7.7k 1.3× 9.2k 2.1× 2.2k 0.5× 113 41.0k
Lillian L. Siu Canada 81 11.6k 0.7× 6.5k 0.8× 5.0k 0.9× 8.2k 1.9× 1.9k 0.5× 579 24.6k
Ruth M. Pfeiffer United States 76 9.6k 0.6× 2.9k 0.3× 2.8k 0.5× 5.1k 1.2× 3.3k 0.8× 548 24.8k
Janet Dancey United States 68 19.9k 1.3× 15.4k 1.8× 6.2k 1.1× 8.6k 2.0× 3.3k 0.8× 205 38.3k
Lisa M. McShane United States 65 12.7k 0.8× 5.1k 0.6× 10.9k 1.8× 9.1k 2.1× 3.4k 0.8× 184 28.1k

Countries citing papers authored by Dongsheng Tu

Since Specialization
Citations

This map shows the geographic impact of Dongsheng Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongsheng Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongsheng Tu more than expected).

Fields of papers citing papers by Dongsheng Tu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongsheng Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongsheng Tu. The network helps show where Dongsheng Tu may publish in the future.

Co-authorship network of co-authors of Dongsheng Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Dongsheng Tu. A scholar is included among the top collaborators of Dongsheng Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongsheng Tu. Dongsheng Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gupta, Arjun, Christopher J. O’Callaghan, Liting Zhu, et al.. (2024). The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17. JNCI Journal of the National Cancer Institute. 116(8). 1313–1318. 7 indexed citations
2.
Titmuss, Emma, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2024). Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research. 30(6). 1121–1130. 3 indexed citations
3.
Kennecke, Hagen F., Christopher J. O’Callaghan, Dongsheng Tu, et al.. (2024). The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.. Journal of Clinical Oncology. 42(16_suppl). TPS3646–TPS3646. 1 indexed citations
4.
Deng, Yangqing, Dongsheng Tu, Chris J. O’Callaghan, et al.. (2023). A Bayesian approach for two‐stage multivariate Mendelian randomization with mixed outcomes. Statistics in Medicine. 42(13). 2241–2256. 1 indexed citations
5.
Gilron, Ian, Dongsheng Tu, Ronald R. Holden, et al.. (2022). Melatonin for Neuropathic Pain: Protocol for a Double-blind, Randomized Controlled Trial. JMIR Research Protocols. 11(9). e40025–e40025. 4 indexed citations
6.
Asleh, Karama, Dongsheng Tu, Dongxia Gao, et al.. (2021). Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. Clinical Cancer Research. 27(23). 6570–6579. 2 indexed citations
7.
Loree, Jonathan M., Dongsheng Tu, Derek J. Jonker, et al.. (2020). Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clinical Cancer Research. 27(1). 52–59. 19 indexed citations
8.
Tinker, Anna V., Holger W. Hirte, Diane Provencher, et al.. (2019). Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. Clinical Cancer Research. 25(20). 6052–6060. 70 indexed citations
9.
Shi, Tingyan, Rong Jiang, Jinjin Yu, et al.. (2018). Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. British Journal of Cancer. 119(1). 12–18. 7 indexed citations
10.
Bernstein, Vanessa, Susan Ellard, Susan Dent, et al.. (2017). A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment. 167(2). 485–493. 79 indexed citations
11.
12.
Gilron, Ian, Luis Enrique Chaparro, Dongsheng Tu, et al.. (2016). Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 157(7). 1532–1540. 78 indexed citations
13.
Gilron, Ian, et al.. (2015). Combination of morphine with nortriptyline for neuropathic pain. Pain. 156(8). 1440–1448. 66 indexed citations
14.
Chia, Stephen, Vivien Bramwell, Dongsheng Tu, et al.. (2012). A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clinical Cancer Research. 18(16). 4465–4472. 220 indexed citations
15.
Cheang, Maggie C.U., K. David Voduc, Dongsheng Tu, et al.. (2012). Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clinical Cancer Research. 18(8). 2402–2412. 105 indexed citations
16.
O’Malley, F., Stephen Chia, Dongsheng Tu, et al.. (2011). Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Research and Treatment. 128(2). 401–409. 35 indexed citations
17.
Tu, Dongsheng, Bent Ejlertsen, Maj‐Britt Jensen, et al.. (2011). TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Research and Treatment. 132(1). 225–234. 10 indexed citations
18.
Pritchard, Kathleen I., Alison F. Munro, Frances P. O’Malley, et al.. (2011). Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Research and Treatment. 131(2). 541–551. 16 indexed citations
19.
Pritchard, Kathleen I., Lois E. Shepherd, Frances P. O’Malley, et al.. (2006). HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. New England Journal of Medicine. 354(20). 2103–2111. 372 indexed citations
20.
Rathee, S, et al.. (2006). A bench‐top megavoltage fan‐beam CT using ‐photodiode detectors. I. System description and detector characterization. Medical Physics. 33(4). 1078–1089. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric J. Feuer Breakdown of academic impact, for papers by Marc Buyse Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Kenneth R. Hess Breakdown of academic impact, for papers by David S. Hong Breakdown of academic impact, for papers by Denis Lacombe Breakdown of academic impact, for papers by Lillian L. Siu Breakdown of academic impact, for papers by Ruth M. Pfeiffer Breakdown of academic impact, for papers by Janet Dancey Breakdown of academic impact, for papers by Lisa M. McShane
Rankless by CCL
2026